Alpelisib Arrives as New Targeted Option for Breast Cancer Subgroup

Brittany Lovely
Published: Tuesday, Aug 20, 2019
 Dejan Juric, MD

Dejan Juric, MD

In May 2019, the FDA approved alpelisib (Piqray) in combination with fulvestrant for the treatment of postmenopausal women and men with hormone receptor (HR)–positive, HER2-negative PIK3CA-mutated advanced or metastatic breast cancer, making it the first targeted therapy in this setting with a predictive biomarker.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication